Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by general360on Sep 16, 2019 10:47am
186 Views
Post# 30131021

RE:Resverlogix Provides Update on BETonMACE Phase 3 Trial

RE:Resverlogix Provides Update on BETonMACE Phase 3 Trial
fantastic news, long overdue!  gonna b a nail biter until the end of the month eh?
quick question for the brain-trust:  what to make of the presentation schedule?
i'll add some bolding cause something jumps out to me:

from the NR:  "expect that BETonMACE’s full outcomes, pre-specified endpoint data, safety results and clinical implications will be reported and published through major conferences and publications in late-2019 and afterward beginning with the American Heart Association (AHA) meeting in November 2019 in Philadelphia, followed by the Clinical trial on Alzheimer’s Disease (CtAD) meeting in December 2019 in San Diego. Data will also be disseminated at leading nephrology meetings."

very specific.  am i to believe that we have landed the late breaking session at AHA then!? to be announced this week?  that hasn't been announced yet, and over at agora BDaz posted a link to some tweets for last week and early this week, so we're waiting for that?

BUT... they have something on the books for CTAD in Dec San Diego?

Guess nothing for ASN Kidney week conference Nov 6-10?
And nothing for CTAD Asia Oct 11-12?

I like the AHA placeholder, and the AD placeholder, where is the placeholder for Renal!?

Go RVX go!!!!

Bullboard Posts